POINT Biopharma Global Inc (NASDAQ: PNT) has a price-to-earnings ratio of 15.29x that is above its average ratio. Additionally, the 36-month beta value for PNT is -0.02. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”

The average price predicted by analysts for PNT is $14.50, which is $0.82 above the current price. The public float for PNT is 87.57M and currently, short sellers hold a 5.01% ratio of that float. The average trading volume of PNT on November 20, 2023 was 2.47M shares.

PNT) stock’s latest price update

POINT Biopharma Global Inc (NASDAQ: PNT)’s stock price has surge by 2.63relation to previous closing price of 13.33. Nevertheless, the company has seen a 4.27% surge in its stock price over the last five trading sessions. Seeking Alpha reported 2023-10-12 that Lantheus Holdings’ stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, has driven significant revenue growth. Lantheus acquired rights to two radioligand drug candidates from Point Biopharma in 2022, targeting prostate cancer and neuroendocrine tumors.

PNT’s Market Performance

PNT’s stock has risen by 4.27% in the past week, with a monthly rise of 6.13% and a quarterly rise of 65.62%. The volatility ratio for the week is 3.97% while the volatility levels for the last 30 days are 2.19% for POINT Biopharma Global Inc The simple moving average for the last 20 days is 5.71% for PNT stock, with a simple moving average of 51.66% for the last 200 days.

Analysts’ Opinion of PNT

Many brokerage firms have already submitted their reports for PNT stocks, with Jefferies repeating the rating for PNT by listing it as a “Buy.” The predicted price for PNT in the upcoming period, according to Jefferies is $14 based on the research report published on July 20, 2023 of the current year 2023.

PNT Trading at 25.83% from the 50-Day Moving Average

After a stumble in the market that brought PNT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.96% of gains for the given period.

Volatility was left at 2.19%, however, over the last 30 days, the volatility rate increased by 3.97%, as shares surge +5.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +74.49% upper at present.

During the last 5 trading sessions, PNT rose by +4.27%, which changed the moving average for the period of 200-days by +68.89% in comparison to the 20-day moving average, which settled at $12.98. In addition, POINT Biopharma Global Inc saw 87.65% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PNT starting from MCCANN JOE A., who purchase 2,160 shares at the price of $6.64 back on Nov 29. After this action, MCCANN JOE A. now owns 3,616,313 shares of POINT Biopharma Global Inc, valued at $14,342 using the latest closing price.

Malik Rajesh, the Director of POINT Biopharma Global Inc, purchase 3,700 shares at $6.66 during a trade that took place back on Nov 28, which means that Malik Rajesh is holding 3,700 shares at $24,642 based on the most recent closing price.

Stock Fundamentals for PNT

Current profitability levels for the company are sitting at:

• +55.40 for the present operating margin
• +99.38 for the gross margin

The net margin for POINT Biopharma Global Inc stands at +43.38. The total capital return value is set at 33.83, while invested capital returns managed to touch 26.49. Equity return is now at value 26.33, with 24.04 for asset returns.

The receivables turnover for the company is 3,410.08 and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.66.

Conclusion

In conclusion, POINT Biopharma Global Inc (PNT) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.